<DOC>
	<DOCNO>NCT00271557</DOCNO>
	<brief_summary>The purpose safety study evaluate NATRECORÂ® hBNP ( recombinant form natural human peptide normally secrete heart response heart failure ) , subject worsen congestive heart failure inpatient intravenous therapy medication influence tone caliber blood vessel deem appropriate .</brief_summary>
	<brief_title>A Study Develop Additional Safety Clinical Experience With NATRECOR hBNP ( Nesiritide ) Treatment Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence Tone Caliber Blood Vessels</brief_title>
	<detailed_description>The data previous study suggest dos NATRECOR® hBNP may potent agent treatment acute congestive heart failure ( CHF ) unique combination desirable effect flow blood throughout body ; hormone secrete nervous system ; support copious salt output renal system provide currently available therapy . The purpose safety study evaluate NATRECOR® hBNP subject symptomatic , decompensated congestive heart failure inpatient intravenous therapy medication influence tone caliber blood vessel ( , addition , IV diuretic ) deem appropriate . This multi-center , randomize , open-label , safety study design compare two dos NATRECOR® hBNP treatment decompensated congestive heart failure . One treatment group receive NATRECOR® hBNP fixed-dose infusion IV bolus 0.3 µg/kg follow 0.015 µg/kg/min infusion ; group two receive IV bolus 0.6 µg/kg follow 0.03 µg/kg/min infusion . The duration NATRECOR® hBNP therapy determine attend physician . The study hypothesis dose NATRECOR® hBNP range 0.015 0.03 µg/kg/min provide optimal safety/efficacy profile treatment decompensated CHF . One treatment group receive NATRECOR® hBNP fixed-dose infusion IV bolus 0.3 µg/kg follow 0.015 µg/kg/min infusion ; group two receive IV bolus 0.6 µg/kg follow 0.03 µg/kg/min infusion . The duration NATRECOR® hBNP therapy determine attend physician .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Patients previous history chronic congestive heart failure ( CHF ) present symptomatic , decompensated CHF inpatient intravenous therapy medication influence tone caliber blood vessel ( , addition , diuretic ) Patients myocardial ischemia within past 48 hour significant valvular stenosis , obstructive cardiomyopathy , constrictive pericarditis primary pulmonary hypertension treat intravenous ( IV ) therapy medication influence tone caliber blood vessel &gt; 4 hour episode CHF already treat IV therapy medication influence tone caliber blood vessel discontinue cardiogenic shock , systolic blood pressure consistently &lt; 90 mm Hg significant blood circulation instability .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Renal Dysfunction</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Decompensation</keyword>
	<keyword>Dyspnea Paroxysmal .</keyword>
</DOC>